Loading...
01/11 11:29
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call summary indicates mixed signals: positive net sales growth and strong liquidity are offset by decreased margins and adjusted EBITDA. The Q&A revealed strong performance in the Americas and APAC, but softer results in Europe. Management's vague responses on EMEA and APAC performance, especially regarding China, and on pricing adjustments add uncertainty. The share repurchase plan is positive but not definitive. Overall, the sentiment is neutral due to the balance of positive and negative factors, with no strong catalysts to drive a significant stock price change in either direction.
Net Sales $297,400,000, an increase of 2.6% year-over-year; driven by strong performance in The Americas with a 6% growth and a 10% increase in currency neutral orders.
Adjusted Gross Profit Margin 37.7%, a decrease of 82 basis points year-over-year; attributed to higher manufacturing and freight costs, partially offset by higher pricing.
Adjusted SG&A Expenses $86,800,000, compared to $86,200,000 in Q1 2024; slight increase year-over-year.
Adjusted Operating Income $25,500,000, flat compared to Q1 2024; no significant change year-over-year.
Adjusted EPS $0.25, compared to $0.24 in Q1 2024; a slight increase year-over-year.
Adjusted EBITDA $37,000,000, down from $38,800,000 in Q1 2024; a decrease year-over-year.
Cash from Operating Activities $11,700,000; a positive outcome as typically the first quarter has the largest use of cash.
Liquidity $397,200,000 at the end of the quarter; strong liquidity position.
Net Debt $205,100,000; reflects total debt minus cash on hand.
Net Leverage Ratio 1.1 times; calculated as net debt divided by the last twelve months of adjusted EBITDA.
Capital Expenditures $7,500,000, compared to $4,000,000 in Q1 2024; an increase year-over-year.
Backlog Up 12% year-over-year; indicates strong order momentum.
New Product Launches: In Q1, Interface launched two carpet tile collections, Material Impressions and Open Road, expanding the i2 portfolio.
Product Innovation Management: Appointment of the first VP of Global Product Category Management to optimize product innovation pipeline.
Market Growth in Education: Global education billings were up 13%, driven by modernization initiatives and regional migration.
Market Growth in Healthcare: Global healthcare billings increased by 16% year over year, supported by strong orders converting to billings.
Market Dynamics in Corporate Office: Corporate office billings were down 7% year over year, but growth is expected as companies refresh their spaces.
Regional Performance: In The Americas, net sales grew 6% and currency neutral orders were up 10%.
EAAA Performance: Currency neutral orders in EAAA were down 6% year over year due to a softer macro environment.
Operational Efficiency: Consolidated currency neutral orders increased 3% year over year, with a strong backlog up 12%.
Cost Management: Plans in place to offset tariff impacts through pricing and productivity.
One Interface Strategy: The One Interface strategy is focused on building global functions, enhancing productivity, and expanding margins.
Sustainability Initiatives: Investment in incorporating captured carbon into manufacturing processes to lower carbon footprint.
Tariff Exposure: The company faces tariff-related costs primarily from U.S. imports of nora rubber from Germany and LVT from South Korea, which represent approximately 15% of global product costs. This translates to an annualized expense of roughly $10 million to $15 million.
Supply Chain Challenges: Despite the tariff exposure, the company benefits from local manufacturing, which mitigates risks associated with tariffs. They have plans in place to offset tariff impacts through pricing and productivity.
Economic Uncertainty: The company operates in a dynamic macro environment with considerable uncertainty, which could affect future performance.
Competitive Pressures: The company is experiencing competitive pressures, particularly in the corporate office segment, which saw a 7% decline in billings year over year. However, they anticipate growth in this segment as companies refresh their office spaces.
Market Dynamics: The company noted a softer macro environment in the EAAA region, impacting orders negatively by 6% year over year.
Return to Office Trends: The return to office dynamics present both risks and opportunities, with companies needing to modernize their office spaces, which could drive demand for the company's products.
One Interface Strategy: A multiyear strategy focused on building strong global functions, enhancing productivity, expanding margins, and leading in design performance and sustainability.
Global Product Category Management: Appointment of a VP to optimize product innovation and align the portfolio with market needs.
Sustainability Initiatives: Investment in incorporating captured carbon into manufacturing processes to lower carbon footprint and meet sustainability commitments.
Product Launches: Introduction of new carpet tile collections to expand the product portfolio.
Q2 2025 Net Sales Guidance: Forecasted net sales of $355 million to $365 million.
Full Year 2025 Net Sales Guidance: Anticipated net sales of $1.34 billion to $1.365 billion.
Q2 2025 Adjusted Gross Profit Margin: Expected to be approximately 37.2%.
Full Year 2025 Capital Expenditures: Projected capital expenditures of approximately $45 million.
Q2 2025 Adjusted SG&A Expenses: Estimated at approximately $90 million.
Q2 2025 Adjusted Effective Income Tax Rate: Expected to be approximately 27.5%.
Full Year 2025 Adjusted Effective Income Tax Rate: Expected to be approximately 27%.
Share Repurchase Program: The company has plans in place to offset tariff-related costs through incremental pricing and productivity, which may include share repurchase strategies.
The earnings call summary indicates strong financial performance, particularly in healthcare and corporate office billings. Despite a slight decline in education billings, the overall growth trends and strategic investments in automation and innovation are promising. The Q&A section reveals analysts' positive sentiment towards healthcare growth and automation benefits, although some concerns remain about margin details. The company's optimistic guidance and strategic focus on market expansion and product innovation suggest a positive outlook. Without market cap data, a precise prediction is challenging, but overall sentiment leans positive, likely resulting in a stock price increase of 2% to 8%.
The earnings call summary and Q&A indicate strong financial performance, operational efficiency, and broad-based growth across markets. The company has exceeded sales guidance, improved margins, and maintains a strong balance sheet. While there are no new partnerships or significant shareholder return announcements, the optimistic guidance and sustainable market share gains suggest a positive outlook. The lack of detailed guidance on specific areas is a minor concern, but overall, the sentiment leans positive with an expected stock price increase of 2% to 8% over the next two weeks.
The financial performance showed slight growth in net sales and EPS, but with decreased gross profit margins due to higher costs. The guidance was slightly raised, indicating cautious optimism. However, macroeconomic uncertainties, supply chain challenges, and competitive pressures present risks. The absence of a share repurchase program and unclear responses in the Q&A section further temper positive sentiment. Overall, the mixed signals and external challenges suggest a neutral outlook for the stock price in the coming weeks.
The earnings call highlights mixed results: a slight revenue increase, stable EPS, and strong backlog growth, but declining gross margins and competitive pressures. The guidance is optimistic, but concerns about tariffs, supply chain, and macroeconomic factors persist. The Q&A reveals management's confidence in pricing strategies and growth in certain regions, but unclear responses about EMEA/APAC performance and tariffs impact raise uncertainties. With no share repurchase program and moderate financial health, the stock price reaction is likely neutral in the absence of a market cap context.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
